Great Basin Scientific Inc (NASDAQ:GBSN) reported the Journal of Clinical Microbiology issued report of a multicenter trial that showed the efficiency of its Staph ID/R Blood Culture Panel in quickly identifying numerous species of Staphylococci and in precisely noticing the mecA gene straight from a positive blood culture.

The trial report, which was performed across 3 clinical sites, showed the efficacy and performance of the Staph ID/R Blood Culture Panel as against the conventional methods, and stated that the firm’s panel offered reduced time to results at a lesser price, assisting physicians diagnose and offer a timely, cost-effective and accurate course of treatment. Great Basin included in the list of best penny stocks in active trading lead failed to record an up move on the charts following this news.

The details

Rob Jenison, the SVP of R&D and Chief Technology Officer at Great Basin, reported that bloodstream infection-related sepsis is a leading cause of mortality and morbidity in the U.S. It is also linked with more than $17 billion in increasing healthcare costs yearly. Traditional blood culture procedures offer physicians with an analysis 48 to 72 hours once a positive sample is known, deferring appropriate treatment and placing the patient at increased risk.

Staph ID/R Blood Culture Panel is established to offer highly actionable and accurate results in less than two hours. The panel potentially removes 32 to 88 hours of unsuitable antibiotic treatment, thereby possibly dropping length of patient stay and enhancing patient care, creating cost and time efficiencies for labs and hospitals of all sizes.

Headed by Dr. Gerald A. Denys, the study established that Great Basin’s panel properly identified promising report for Staphylococcus species 99.4% of the time and negative report was correctly identified 99.9% of the time.

The firm reported the commercial release of the Staph ID/R Blood Culture Group in Europe and the U.S. in September 2016.